Tranzyme's $20M round takes lead therapy to Phase III

With its lead therapy as little as two years from approval, Durham, NC-based Tranzyme has pocketed a $20 million injection from its venture backers. The biotech is developing therapies for post-operative ileus and diabetic gastroparesis. TZP-101 is being tested in Phase IIb trials to determine if it is more effective than standard therapy. Data is expected this spring with a round of final testing to get started soon after. Thomas, McNerney & Partners, Quaker BioVentures and H.I.G. Ventures are gambling their money that Tranzyme can deliver. "This capital will allow us to bring our first-in-class GI motility drug, TZP-101, into Phase III clinical studies for multiple indications," said CEO Vipin K. Garg, Ph.D. Tranzyme was a 2005 Fierce 15 company.

- check out the release
- here's the report from the News & Observer

ALSO: San Diego-based Novalar Pharmaceuticals has closed a $30 million Series D financing. The money is being used to support the U.S. launch of NV-101, a first-in-class, local dental anesthetic reversal agent, and the development of other dental pharmaceuticals in Novalar's pipeline. Release

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.